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Abstract
The expansion of a hexanucleotide repeat GGGGCC in C9orf72 is the most common known cause of ALS
accounting for ~ 40% familial cases and ~ 7% sporadic cases in the European population. In most people, the
repeat length is 2, but in people with ALS, hundreds to thousands of repeats may be observed. A small proportion
of people have an intermediate expansion, of the order of 20 to 30 repeats in size, and it remains unknown
whether intermediate expansions confer risk of ALS in the same way that massive expansions do. We investigated
the association of this intermediate repeat with ALS by performing a meta-analysis of four previously published
studies and a new British/Alzheimer’s Disease Neuroimaging Initiative dataset of 1295 cases and 613 controls. The
final dataset comprised 5071 cases and 3747 controls. Our meta-analysis showed association between ALS and
intermediate C9orf72 repeats of 24 to 30 repeats in size (random-effects model OR = 4.2, 95% CI = 1.23–14.35,
p-value = 0.02). Furthermore, we showed a different frequency of the repeat between the northern and
southern European populations (Fisher’s exact test p-value = 5 × 10− 3). Our findings provide evidence for the
association between intermediate repeats and ALS (p-value = 2 × 10− 4) with direct relevance for research and
clinical practice by showing that an expansion of 24 or more repeats should be considered pathogenic.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disease, primarily affecting upper and lower motor
neurons, resulting in progressive weakness and culmi-
nating in death from neuromuscular respiratory failure,
typically 2–5 years after diagnosis [1]. The incidence is
1–2 per 100,000 person-years, point prevalence is 3 to 5
per 100,000 people in Europe and the United States, and
the lifetime risk is 1 in 300 [2–4].
Following initial linkage and association studies, the
massive expansion of a hexanucleotide repeat in the
C9orf72 gene was found to be the most frequent cause
of ALS [5–10]. In most people, the repeat length is 2,
but in people with ALS, hundreds to thousands of re-
peats may be observed [11]. A small proportion of people
have an intermediate expansion, of the order of 20 to 30
repeats in size and several studies suggest that a threshold
of 20 or 23 repeats could be used to discriminate between
pathogenic and neutral expansions [7, 11–16]. However,
the rarity of intermediate repeats and the consequential
lack of statistical power, has limited the validity of these
results and it remains unknown whether intermediate ex-
pansions confer risk of ALS in the same way that massive
expansions do. At present, a repeat length of > 30 is typic-
ally used as the threshold to distinguish between neutral
and pathogenic expansions [5].
One meta-analysis based on four studies, suggested an
association of intermediate expansions between 24 and
30 repeats in size with sporadic ALS (chi-squared
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p-value = 0.03, fixed-effect model) [17]. However, while
this meta-analysis was rigorous, it had a few limitations
which prevented the results translating into research and
medical practice. First, several studies were excluded
because data on repeats of length < 30 were not available
[17]. Second, the fixed-effect model used in the
meta-analysis assumes that the genetic effects are the
same across the combined investigations, and that all
differences are due to chance [18, 19]. While this
assumption appears to be supported by the lack of het-
erogeneity across the involved studies (Q-test p-value =
0.61), heterogeneity may be masked. Genetic effects may
vary across different populations for various reasons, in-
cluding both genuine differences and differential biases
and errors across studies [20, 21], and the C9orf72 re-
peat expansion exemplifies this variation [13, 15, 16, 22,
23]. Moreover, the Q-test and I-squared do not describe
heterogeneity well when the number of studies is small
[24, 25] and the datasets did not provide sufficient
power to properly test the meta-analysis studies for het-
erogeneity. Third, other studies of intermediate repeat
sizes have been inconclusive [5, 7, 14].
Taking these considerations into account, we there-
fore analysed a new group of 1295 people with ALS
and 613 controls, all sized for C9orf72 repeats, and
included the findings in a meta-analysis of studies
for which there are data on intermediate repeats of
size 24 or greater. We did not investigate intermedi-
ate repeats of size 20 to 23 since such repeats have
been observed both in ALS patients and controls
with no differences in allele distribution in several
studies [5, 16, 23], including in our new cohort
(Fig. 1 and Additional file 1: Table S1).
Methods
Whole-genome sequencing samples
Whole-genome sequencing (WGS) data were obtained
from blood samples of 1908 individuals, comprising
1295 people with ALS (all apparently sporadic cases)
and 613 unaffected controls from two groups: a UK set
of 1295 ALS cases, 340 matched controls [26], and 273
controls from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) WGS dataset (http://adni.loni.usc.edu).
The UK dataset was generated as part of Project MinE
[26, 27], on the Illumina Hiseq X platform (150 bp
paired-end reads) and the ADNI dataset on the Illumina
2000 platform (100 bp paired-end reads).
Genotyping
We used ExpansionHunter [28] to size the C9orf72
GGGGCC repeat in the WGS data. ExpansionHunter
has been previously validated for C9orf72 repeat siz-
ing in 5787 WGS samples from Project MinE that
were also genotyped using repeat-primed polymerase
chain reaction (PCR) and fluorescence PCR. Using
the repeat-primed PCR calls as the gold standard,
ExpansionHunter showed an expansion detection ac-
curacy > 99% [28]. ExpansionHunter also showed high
concordance with PCR and Sanger sequencing in re-
peats whose total length did not exceed the
read-length [28, 29], while providing a confidence
interval for longer repeats. We used the Expansion-
Hunter repeat length called when repeat sizes had a
read length < 25 repeats for the UK dataset and < 17
repeats for the ADNI dataset to account for the dif-
ference in sequencing platform, and we used the
Fig. 1 Distribution of the samples carrying at least one allele of N repeats (x axis) in our dataset (British/ADNI) for cases (blue) and
controls (orange)
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middle value of the confidence interval for longer
repeats.
Meta-analysis and statistics
For meta-analysis, we selected studies for which data
were available for repeats of size 24 or more [17]. Asso-
ciation between the number of repeats and disease status
was analysed by chi-square and Fisher’s exact tests, with
the samples split into two categories: samples with an
intermediate expansion of 24–30 repeats and the remain-
der including those with repeat length > 30. Heterogeneity
across studies was examined using the I-squared statistic
and chi-square-based Q-tests. The Q-test power was cal-
culated using the Jackson method [25]. Both fixed-effect
and random-effects models were used. Sensitivity analyses
were conducted to evaluate the influence of individual re-
sults on the pooled estimate after sequential removal of
each study. Potential publication bias was assessed by both
Begg and Egger tests. The Kolmogorov-Smirnov test
was used to assess the difference of the repeat length
distributions between cases and controls. To test the
phenotype differences between our intermediate repeat
carriers (> 23 and < = 30), the expansion carriers (> 30)
and the non-expanded patients (< 24), we used the log-
rank test to compare the survival distributions, Pearson’s
chi-squared test for gender and site of onset and the
Kolmogorov–Smirnov test for the age at onset. The Q-test
power calculation was made using Stata 15 (Stata Corp,
College Station, TX, USA). All other analyses were done
in R 3.4.4 using the Metabin function of the Meta library
[30]. The p-value threshold used in this study to indicate
statistical significance was 0.05.
Alzheimer’s Disease Neuroimaging Initiative
Data used in the preparation of this article were ob-
tained from the Alzheimer’s Disease Neuroimaging Ini-
tiative (ADNI) database (adni.loni.usc.edu). The ADNI
was launched in 2003 as a public-private partnership, led
by Principal Investigator Michael W. Weiner, MD. The
primary goal of ADNI has been to test whether serial
magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to
measure the progression of mild cognitive impairment
(MCI) and early Alzheimer’s disease (AD).
Results
C9orf72 repeat expansion distribution in the new cohort
For the British dataset, the median age of ALS onset was
62.4 years and for controls, 60.1 years, with a male-
female ratio of 62:38. In the ADNI dataset the median
age was 73.2 and the male-female ratio 49:51.
We identified no difference in the distributions of
repeat size between ALS and controls in the 1–23
repeat interval (Kolmogorov-Smirnov test, p-value =
0.96). Nine cases and one control were found to
carry 24–30 repeats. Five controls were found to
carry expansions whose length is rarely seen in
unaffected controls and among which a few were
hundreds of repeats long (Fig. 1 and Additional file
1: Table S1). Specifically, five British controls carried
large expansions up to hundreds of repeats (sizes 60,
357, 406, 413 and 484) and one British control car-
ried an intermediate repeat expansion of 26 repeats.
6.6% of cases had a repeat of size > 30.
Meta-analysis of the 24–30 repeat expansion
A literature review [17] identified four studies which
provided original data on the number of patients carry-
ing 24–30 repeats, including one study from North
America [23], one study from Italy [16], one study from
France [15], and one study from Spain [13]. We ex-
tended the review to all articles published up to January
2019 and identified one further study [28] providing data
suitable for our meta-analysis. However, in this
additional study, most of the ALS cases overlapped with
our British dataset, and we therefore excluded it from
our analysis. Therefore, after reproducing the previously
published meta-analysis, we performed two new
meta-analyses. In the first we added our British samples
(1295 cases and 340 controls) and in the second we
added our British/ADNI dataset (1295 cases and 613
controls). The final dataset used in this study comprised
5071 cases and 3747 controls. We were able to repro-
duce the association between the C9orf72 24–30 repeat
expansion and ALS using the previously used four
datasets (fixed-effect model odds ratio = 5.13, 95% confi-
dence interval = 1.28–22.24, p-value = 0.03) (Table 1A).
The association was replicated after including our co-
horts, both when the British cohort was added (fixed-effect
model odds ratio = 4.01, 95% confidence interval = 1.21–
13.26 p-value = 0.02) (Table 1B) and when the British/
ADNI dataset was added (fixed-effect model odds ratio =
4.82, 95% confidence interval = 1.45–15.96, p-value = 0.01)
(Table 1C). The use of the fixed-effect model was suggested
by the chi-square Q-test which did not show heterogeneity
(p-value = 0.61), but this was underpowered to detect het-
erogeneity (power = 12.07%), suggesting that a random-
effects model is a more appropriate model to use. Under
a random-effects model, we did not show association
using the four studies from the previous meta-analysis
only (p-value = 0.07). Using the UK/ADNI dataset we
were able to show this association under the
random-effects model hypothesis also (odds ratio = 4.2,
95% confidence interval = 1.23–14.35, p-value = 0.02)
(Table 1C).
No evidence of publication bias from either the
Egger (p-value = 0.69) or Begg (p-value = 0.14) test
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was observed (Additional file 1: Figure S1). Sensitiv-
ity testing, recalculating the pooled odds ratios by
omitting one study per iteration (Additional file 1:
Table S2) showed that results were consistent, with-
out major fluctuations.
Association between C9orf72 intermediate expansion on
the aggregated dataset
We also investigated the association between the inter-
mediate repeats and ALS in a final dataset generated
from the aggregation of the 5 datasets used for the
Table 1 Meta-analyses on the influence of C9orf72 24–30 repeat-long expansions on the risk of ALS. (A) Replication of the previously
published meta-analysis (Y. Chen et al.). (B) Adding our British dataset to the 4 used in Y. Chen et al. (C) Adding our British/ADNI
dataset to the 4 used in Y. Chen et al
N. of samples 24–30 repeats
Cases/Controls






A - Y. Chen et al. meta-analysis datasets
Garcia-Redondo et al. 1/0 781/248 0.95 0.04 23.52 32.8/22.7
Ratti et al. 1/0 1275/862 2.03 0.08 49.89 25.8/22.7
Rutherford et al. 3/0 995/1444 10.19 0.53 197.45 17.6/26.5
Millecamps et al. 6/0 725/580 10.19 0.59 186.57 23.8/28.1
M-H pooled (fixed-effect) 11/0 3776/3134 5.13 1.18 22.24 100.0
M-H pooled (random-effects) 11/0 3776/3134 4.16 0.90 19.14 100.0
Heterogeneity chi-squared Q = 1.82 (d.f. = 3) p = 0.61, power = 12.07%
I-squared (variation in OR attributable to heterogeneity) = 0.0% (0.0–74.8%)
Fixed-effect Test of OR = 5.13: z = 2.18 p = 0.03
Random-effects Test of OR = 4.16: z = 1.83 p = 0.07
B - Y. Chen et al. meta-analysis datasets + our British dataset
Garcia-Redondo et al. 1/0 781/248 0.95 0.04 23.52 19.5/14.7
Ratti et al. 1/0 1275/862 2.03 0.08 49.89 15.3/14.7
Rutherford et al. 3/0 995/1444 10.19 0.53 197.45 10.5/17.2
Millecamps et al. 6/0 725/580 10.49 0.59 186.57 14.2/18.2
British dataset 9/1 1295/340 2.37 0.30 18.79 40.5/35.2
M-H pooled (fixed-effect) 20/1 5071/3474 4.01 1.21 13.26 100.0
M-H pooled (random-effects) 20/1 5071/3474 3.41 1.00 11.66 100.0
Heterogeneity chi-squared Q = 2.00 (d.f. = 4), p = 0.74, power = 12.83%
I-squared (variation in OR attributable to heterogeneity) = 0.0% (0.0–58.4%
Fixed-effect Test of OR = 4.01: z = 2.28 p = 0.02
Random-effects Test of OR = 3.41: z = 1.96 p = 0.05
C - Y. Chen et al. meta-analysis datasets + our British/ADNI dataset
Garcia-Redondo et al. 1/0 781/248 0.95 0.04 23.52 20.7/14.7
Ratti et al. 1/0 1275/862 2.03 0.08 49.89 16.3/14.7
Rutherford et al. 3/0 995/1444 10.19 0.53 197.45 11.1/17.2
Millecamps et al. 6/0 725/580 10.49 0.59 186.57 15.0/18.2
British/ADNI dataset 9/1 1295/613 4.28 0.54 33.88 36.9/35.2
M-H pooled (fixed-effect) 20/1 5071/3747 4.82 1.45 15.96 100.0
M-H pooled (random-effects) 20/1 5071/3747 4.20 1.23 14.35 100.0
Heterogeneity chi-squared Q = 1.80 (d.f. = 4), p = 0.77, power = 13.01%
I-squared (variation in OR attributable to heterogeneity) = 0.0% (0.0–53.7%)
Fixed-effect Test of OR = 4.82: z = 2.57 p = 0.01
Random-effects Test of OR = 4.20: z = 2.29 p = 0.02
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meta-analysis (5071 cases and 3747 controls). The asso-
ciation was demonstrated both with the chi-squared test
(p-value = 5 × 10− 4, odds ratio = 14.83, 95% confidence
interval 1.99–110.57) and the Fisher’s exact test
(p-value = 2 × 10− 4). Considering that the frequency of
the C9orf72 expanded repeat greatly varies across Euro-
pean populations [5, 7, 13–15, 31], we attempted to
investigate whether this is also true for the intermediate
repeats. To do so we split the aggregated dataset cases
in two groups, 3015 northern European patients (Ameri-
cans, French and British) and 2056 southern European
patients (Italians and Spanish). Both the chi-squared test
(p-value = 5 × 10− 3, odds ratio = 6.17, 95% confidence
interval 1.43–26.61) and the Fisher’s exact test (p-value =
5 × 10− 3) showed a significant difference between the
two groups. On the basis of intermediate repeat hetero-
geneity between the two groups, we tested the associ-
ation between the intermediate repeats and ALS in the
two groups separately. For the northern European dataset
(3015 cases and 2637 controls) the resulting odds ratio
was 15.83 (95% confidence interval 2.11–118.67,
chi-squared p-value = 3 × 10− 4 and Fisher’s exact test
p-value = 10− 4). In the southern European dataset (2056
cases and 1110 controls) the association was not signifi-
cant (Fisher’s exact test p-value = 0.54). However, the
low frequency of intermediate expansions (< 0.1% in
cases and not present in controls) limits the statistical
power to conclude if there is an association in this group
(power < 10%).
Clinical phenotype analysis
For our 1295 British patients, we compared the age
at onset, time from first symptom to death (or last
visit for censored cases) and site of onset (bulbar or
spinal), between the patients who carried a non-
expanded number of repeats (< 24 in 1201 patients),
an intermediate number of repeats (> 23 and < = 30 in
9 patients) and a full expansion (> 30 in 85 patients).
We found no significant differences between the
intermediate repeat carriers and the other patients.
Consistent with previous findings [11, 32–34], pa-
tients carrying a full expansion had a shorter survival
time (p-value < 0.0001, median = 2.49 years and 25–
75% quantiles = 1.88–3.71 years) and a younger age at
onset (p-value = 0.009, mean = 58.39 ± 8.46 years) com-
pared to patients carrying a non-expanded number of
repeats (survival median = 3.01 years and 25–75%
quantiles = 2.10–4.55 years, mean age at onset =
60.90 ± 11.13 years). No difference in terms of gender
prevalence and site of onset were observed between
the three groups. A demographic table for the three
groups is available in the Supplementary material
(Additional file 1: Table S2).
Discussion
We have shown that intermediate repeat expansions in
the C9orf72 gene are associated with ALS. An expanded
hexanucleotide repeat in C9orf72 is the most common
cause of ALS. While expansions of hundreds of repeats
in size are clearly associated with the disease, a lower
limit has not yet been identified. A few studies have
suggested that 24–30 repeats might be sufficient to
cause the disease [12, 17]. However, considering that
the statistical power of the datasets used was limited,
further investigation was essential. We have added
1295 cases and 613 controls to the meta-analysis and
demonstrated the association of such intermediate
expansions with ALS both under a fixed-effect
(p-value = 0.01) and a random-effects model (p-value =
0.02). The latter tells us that the association between
24 and 30 repeats and the disease exists without as-
suming that the effect of this mutation is
homogenous across the patient groups. This up-to-
date figure obtained from a meta-analysis on 5071
ALS patients and 3747 controls from 5 populations
(UK, USA, Spain, Italy and France) provides definitive
evidence for the association between intermediate re-
peats and ALS (p-value = 2 × 10− 4) and expands the
role of C9orf72 in the development of ALS by enlar-
ging the number of cases that can be explained, with
direct implications for research and clinical practice.
Indeed, we suggest the threshold to discriminate be-
tween neutral and pathogenic C9orf72 expansions
should be lowered to 23, considering as pathogenic,
expansions of 24 or more repeats, in agreement with
previously reported observations [5, 17].
Expansions of 20–23 repeats have contradictory
evidence of association with ALS. This suggests that
if such an association exists, their contribution to
disease risk is weaker than for longer expansions,
and we need larger datasets to investigate it. Due to
the very low frequency of intermediate repeats, fur-
ther investigation and larger sample sizes are needed
to consolidate our results and determine whether to
lower the threshold further. International initiatives
such as Project MinE, whose aim is to collect gen-
etic data (including the length of the C9orf72 repeat)
of over 10,000 thousand people with ALS, will be
crucial to this end. Interestingly, we also observed a
few controls with very large expansions that are only
rarely observed in non-affected individuals. We have
openly released the repeat frequency in our cohort
for a wide range of lengths, to allow further analysis
when new cohorts become available (Additional file
1: Table S1). Finally, we looked at age at onset, sur-
vival time, gender prevalence and site of onset of the
intermediate repeat carriers, and we found no
significant differences from the other patients.
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However, this analysis was limited by their small
number (9), which does not allow us to make any
conclusion about the clinical characterization of this
sub-group of patients.
Additional file
Additional file 1: Figure S1. Bias detection in the meta-analysis: A) Egger
test; B) Begg test. C) Funnel plot of the 5 studies used in our meta analysis.
Table S1. C9orf72 expansion analysis results obtained with ExpansionHunter
on the British/ADNI dataset. Table S2. Pooled odds ratios by omitting one
study per iteration. Demographic table. (DOCX 3047 kb)
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